NCT05443139

Brief Summary

This study evaluates the effectiveness of an online Multi-component psychological intervention, that is focused on providing self-support to the population of 5 Latin American countries and 2 European Countries. The objectives of the intervention are: 1) To reduce the symptoms of anxiety and depression in the adult population, 2) To increase the levels of subjective well-being.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable anxiety

Timeline
Completed

Started Dec 2022

Typical duration for not_applicable anxiety

Geographic Reach
6 countries

8 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 22, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 5, 2022

Completed
6 months until next milestone

Study Start

First participant enrolled

December 23, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 23, 2023

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

January 18, 2023

Status Verified

January 1, 2023

Enrollment Period

1 year

First QC Date

June 22, 2022

Last Update Submit

January 16, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • Decrease in the scores of the Center for Epidemiologic Studies Depression (CESD-R) scale

    Center for Epidemiologic Studies Depression (CES-D) is a structured self-report scale for evaluation depression symptoms. This scale assesses the number of depression symptoms within 2 weeks. The scale consists 20 items and contains 4-point score responses (0 to 3) as the following; rarely or none of the time (less than 1 day); some of a little of the time (1-2 days); occasionally or moderate amount of time (3-4 days) and most or all of the time (5-7 days). The total possible range of scores is from 0 to 60 where \^16 is the cut-off point for this scale, and higher scores indicate more symptoms of depression. It is expected a statistically significant decrease (P \< 0.05) in depression symptoms.

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • Decrease in the score of the General Anxiety Disorder with 7-items (GAD-7) scale

    Is a short scale with items that measure the severity of generalized anxiety disorder symptoms. Responses are based on symptoms perceived during the past week. The questions of this scale are answered in Likert format with 0-3, where the maximum total score is 21. A score between 0 and 4 points indicates that anxiety is not perceived, and a score between 15 and 21 is an indicator of perceived severe anxiety.It is expected a statistically significant decrease (P \< 0.05) in anxiety symptoms.

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • Increase in Mental Psychological Well-being, the Warwick-Edinburgh Mental Well-being Scale (WEMWBS)

    It consists of 14 items, including hedonic (i.e. affects, life satisfaction) and eudaimonic (i.e. positive relationships, psychological functioning) items, which together measure mental well-being. Each item is responded in a Likert scale (i.e. 1 = none of the time to 5 = all of the time) and the total score ranges from 14 to 70. The higher the score, the higher the mental well-being

    Time Frame: 1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

Secondary Outcomes (7)

  • Decrease in The Perceived Stress Scale (PSS-10)

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • Decrease in the score of The Pittsburgh Sleep Quality Index

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • Decrease in the Action Acceptance Questionnaire II (AAQ-II)

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • Increase in The Satisfaction with Life scale

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • Decrease in the Perceived Deficits Questionnaire or PDQ-5

    1 to 1.5 months, depending on the development of the patient and the completion of the 10 modules

  • +2 more secondary outcomes

Study Arms (3)

Interactive intervention

EXPERIMENTAL

The participants will receive a self-applied intervention composed by 10 sessions following a multi component structure. The participants assigned to this condition will count with interactive resources such as Videos, Online Forum and Exercises embedded on the platform.

Behavioral: Well-being online

non-interactive intervention

EXPERIMENTAL

Self-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.

Behavioral: Well-being online

Waiting List group

NO INTERVENTION

The control condition consists of a 30-day waiting list, in which participants will not be able to access the interventions. After the waiting process, they will be given access to either the interactive intervention or the non-interactive intervention.

Interventions

Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).

Interactive interventionnon-interactive intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older
  • Completion of 100% of the basal evaluation through the form
  • Residence in one of the countries participating in the study
  • Fluency/ proficiency in Spanish (Mexico, Ecuador, Chile, Peru and Spain), Dutch or English (Netherlands) or Portuguese (Brazil), depending on the country.

You may not qualify if:

  • Participants with severe symptoms of anxiety and/or depression, or they report a diagnosis of a depression and/or an anxiety disorder.
  • Participants who self-report having another diagnosed psychiatric comorbidity: personality disorder, psychotic disorder, bipolar disorder, Attention-Deficit/Hyperactivity Disorder, or others.
  • Participants taking medication for symptoms of depression and/or anxiety

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Universidade Federal da Bahia

Ondina, Brazil

NOT YET RECRUITING

Universidad Internacional de Ecuador

Quito, Ecuador

NOT YET RECRUITING

Universidad Autónoma de Ciudad Juárez

Juárez, Chihuahua, 32315, Mexico

RECRUITING

Tecnólogico de Monterrey

Guadalajara, Mexico

NOT YET RECRUITING

Universidad de Guadalajara

Guadalajara, Mexico

NOT YET RECRUITING

University of Tilburg

Tilburg, Netherlands

NOT YET RECRUITING

Instituto Peruano de Orientación Psicológica

Lima, Peru

NOT YET RECRUITING

Universidad Internacional de Valencia

Valencia, Spain

NOT YET RECRUITING

Related Publications (17)

  • Piqueras Rodríguez, J. A., Martínez González, A. E., Ramos Linares, V., Rivero Burón, R., García López, L. J., & Oblitas Guadalupe, L. A. (2008). Ansiedad, depresión y salud (Anxiety, depression and health). Suma Psicológica, 15, 43-74.

    BACKGROUND
  • Podlogar MC, Rogers ML, Stanley IH, Hom MA, Chiurliza B, Joiner TE. Anxiety, depression, and the suicidal spectrum: a latent class analysis of overlapping and distinctive features. Cogn Emot. 2018 Nov;32(7):1464-1477. doi: 10.1080/02699931.2017.1303452. Epub 2017 Mar 20.

    PMID: 28317414BACKGROUND
  • Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. 2012 Oct 1;36(5):427-440. doi: 10.1007/s10608-012-9476-1. Epub 2012 Jul 31.

    PMID: 23459093BACKGROUND
  • A-Tjak JG, Davis ML, Morina N, Powers MB, Smits JA, Emmelkamp PM. A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychother Psychosom. 2015;84(1):30-6. doi: 10.1159/000365764. Epub 2014 Dec 24.

    PMID: 25547522BACKGROUND
  • Bolier L, Haverman M, Westerhof GJ, Riper H, Smit F, Bohlmeijer E. Positive psychology interventions: a meta-analysis of randomized controlled studies. BMC Public Health. 2013 Feb 8;13:119. doi: 10.1186/1471-2458-13-119.

    PMID: 23390882BACKGROUND
  • Gal E, Stefan S, Cristea IA. The efficacy of mindfulness meditation apps in enhancing users' well-being and mental health related outcomes: a meta-analysis of randomized controlled trials. J Affect Disord. 2021 Jan 15;279:131-142. doi: 10.1016/j.jad.2020.09.134. Epub 2020 Oct 7.

    PMID: 33049431BACKGROUND
  • Ekers D, Webster L, Van Straten A, Cuijpers P, Richards D, Gilbody S. Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis. PLoS One. 2014 Jun 17;9(6):e100100. doi: 10.1371/journal.pone.0100100. eCollection 2014.

    PMID: 24936656BACKGROUND
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092.

  • Carleton RN, Thibodeau MA, Teale MJ, Welch PG, Abrams MP, Robinson T, Asmundson GJ. The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS One. 2013;8(3):e58067. doi: 10.1371/journal.pone.0058067. Epub 2013 Mar 1.

  • Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.

  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

  • Bond FW, Hayes SC, Baer RA, Carpenter KM, Guenole N, Orcutt HK, Waltz T, Zettle RD. Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther. 2011 Dec;42(4):676-88. doi: 10.1016/j.beth.2011.03.007. Epub 2011 May 25.

  • Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. J Pers Assess. 1985 Feb;49(1):71-5. doi: 10.1207/s15327752jpa4901_13.

  • Strober LB, Binder A, Nikelshpur OM, Chiaravalloti N, DeLuca J. The Perceived Deficits Questionnaire: Perception, Deficit, or Distress? Int J MS Care. 2016 Jul-Aug;18(4):183-90. doi: 10.7224/1537-2073.2015-028.

  • Sevilla-Gonzalez MDR, Moreno Loaeza L, Lazaro-Carrera LS, Bourguet Ramirez B, Vazquez Rodriguez A, Peralta-Pedrero ML, Almeda-Valdes P. Spanish Version of the System Usability Scale for the Assessment of Electronic Tools: Development and Validation. JMIR Hum Factors. 2020 Dec 16;7(4):e21161. doi: 10.2196/21161.

  • Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.

  • Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007 Nov 27;5:63. doi: 10.1186/1477-7525-5-63.

MeSH Terms

Conditions

Anxiety DisordersDepression

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehavior

Study Officials

  • Mercedes Almela Zamorano, PhD

    Tilburg University

    STUDY CHAIR
  • Reyna Jazmín Martínez Arriaga, PhD

    University of Guadalajara

    STUDY CHAIR
  • David Villarreal Zegarra, MD

    Instituto Peruano de Orientación Psicológica

    STUDY CHAIR
  • Leivy Patricia González Ramírez, PhD

    Tecnologico de Monterrey

    STUDY CHAIR
  • Adrián Antonio Cisneros Hernández, PhD

    University of Guadalajara

    STUDY CHAIR
  • Marinna Simões Mensorio, PhD

    Independent Researcher

    STUDY CHAIR
  • Rosa Olimpia Castellanos-Vargas, PhD

    Universidad Autónoma de Ciudad Juárez

    STUDY CHAIR
  • Rogéria Lourenço dos Santos, PhD

    Independent Researcher

    STUDY CHAIR
  • Joel Omar González Cantero, PhD

    University of Guadalajara

    STUDY CHAIR
  • Viviana Sylvia Vargas Salinas, PhD

    Independent Researcher

    STUDY CHAIR
  • Joaquín Mateu Mollá, PhD

    Universidad Internacional de Valencia

    STUDY CHAIR
  • Flor Rocío Ramírez Martínez, PhD

    Universidad Autónoma de Ciudad Juárez

    STUDY CHAIR
  • Antonio Carlos Santos da Silva, MD

    Universidad Federal da Bahia

    STUDY CHAIR

Central Study Contacts

Alejandro Domínguez Rodríguez, PhD

CONTACT

Paulina Erika Herdoiza-Arroyo, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The patients are not aware that there are another experimental group and a control group. The conditions of the study are only known by the researcher and the Research Ethics Committee of the Universidad Autónoma de Ciudad Juárez.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The Well-being Online study will implement a randomized controlled trial at five points for the intervention groups and six evaluation periods for the control group: 1)pretest, 2)middle of the treatment, 3) post-test, 4) follow up at 3 months and 5) follow up at six months. 6) Participants in the control group will be re-assigned to the intervention group after the post-waiting list period. The study will implement a three-arm design (parallel group), comparing: 1. Interactive Intervention Group , 2. Intervention delivered through PDF files. 3. Control group.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 22, 2022

First Posted

July 5, 2022

Study Start

December 23, 2022

Primary Completion

December 23, 2023

Study Completion

November 1, 2024

Last Updated

January 18, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will share

The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.

Shared Documents
ICF
Time Frame
This data will be available approximately in September 2023 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published.
Access Criteria
Through the servers of the journal(s) where we will publish the articles.

Locations